Addiction care has already had a venture cycle. That is an advantage.
The companies before us spent more than half a billion dollars proving that patients will receive addiction treatment virtually, clinicians can deliver it, and insurers will pay for it. Some have built large, durable businesses. None has yet produced the obvious venture outcome the size of the market seemed to promise.
One explanation is that addiction is simply a difficult venture category. We think the more interesting lesson is about the companies.
A virtual clinic looks like software from the outside. Underneath, someone still has to find the patient, contract with their insurer, recruit and credential the clinician, schedule the visit, submit the claim, chase the denial and notice when the patient disappears. Software can make each step better without changing the shape of the business. If twice the patients eventually require twice the organization, you have built a better clinic, not a different kind of company.
This is the problem Grata has gradually become organized around.
The constraints keep moving. Demand arrived first: Sobo has grown to 64,811 downloads, and 1,618 people have already completed clinical intakes asking us for insured care in states where Grata is not yet live. Then clinical supply became the bottleneck. We built a recruiting system that has completed 327 AI interviews and extended 109 offers. Now the constraint is increasingly payer activation: getting those clinicians credentialed and able to see patients.
Underneath each constraint, we are building the system that should make encountering it a second time easier.
Grata now owns its clinical + operational software end to end. It autonomously submits 100% of initial claims, with a 90% net collection rate. The same three-person engineering team supports our consumer products, clinical operations, provider workforce, revenue cycle and partnership infrastructure. We will always need more clinicians as we treat more patients. We should not need proportionately more people recruiting, credentialing, scheduling, billing and coordinating them. That is the bet.
The first generation proved demand, reimbursement and clinical delivery. What they could not yet prove was whether the institution underneath the care could gain operating leverage as it grew.
We get to start where they left off.
If we are wrong, Grata will eventually look like the companies that came before it.
If we are right, they were not wrong.
They were too early.